间充质干细胞治疗肺纤维化的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (7): 1056-1059.

间充质干细胞治疗肺纤维化的研究进展

陈民佳, 汪晓月, 陈客宏, 陆红祥^*

陆军军医大学大坪医院消化内科,重庆 400042

收稿日期:2020-08-04 修回日期:2020-12-15 出版日期:2021-07-05 发布日期:2021-06-17
通讯作者: *18908373382@163.com
基金资助:
国家自然科学基金(81770731); 重庆市技术创新与应用发展专项(cstc2019jscx-msxmX0258)

Research progress of mesenchymal stem cells in the treatment of pulmonary fibrosis

CHEN Min-jia, WANG Xiao-yue, CHEN Ke-hong, LU Hong-xiang^*

Department of Gastroenterology, Daping Hospital, the Army Medical University, Chongqing 400042, China

Received:2020-08-04 Revised:2020-12-15 Online:2021-07-05 Published:2021-06-17
Contact: *18908373382@163.com

摘要/Abstract

摘要： 肺纤维化(PF)尚无有效的治疗药物和干预方法。间充质干细胞 (MSCs) 治疗特发性肺纤维化(IPF)、放射性肺纤维化(RPF)等类型PF的机制有多种,包括通过旁分泌作用,释放白细胞介素-1受体拮抗剂、抑制白细胞介素-1和肿瘤坏死因子-α的表达、抵抗组织炎性反应、增加肝细胞生长因子(HGF)信号传导、抑制PI3K/AKT/mTOR活化、降低肺泡Ⅱ上皮细胞(ATⅡ)的上皮细胞间充质转化(EMT)、减轻肺组织细胞凋亡和纤维化等等。此外,还有促进组织抗感染、抗纤维化等功能、延缓器官纤维化。通过本文所述能够为MSCs治疗器官纤维化提供一些可行的研究思路。

关键词: 间充质干细胞(MSCs), 治疗, 肺纤维化(PF), Wnt信号通路, 肝细胞生长因子(HGF)

Abstract: There is no effective therapeutic drug and intervention method for pulmonary fibrosis(PF). There are many mechanisms of using mesenchymal stem cell in the treatment of idiopathic pulmonary fibrosis(IPF), radiation pulmonary fibrosis(RPF) and other types of PF as follows: paracrine impact, release of leukocyte mediator-1 receptor antagonist, inhibition of the expression of interleukin-1 and tumor necrosis factor-α, and resistant to tissue inflammation,increase of signal transduction for hepatocyte growth factor(HGF),inhibition of PI3K/AKT/mTOR activation and epithelial mesenchymal transformation(EMT) in alveolar Ⅱ epithelial cells(ATⅡ),lung tissue apoptosis and fibrosis, promotion of tissue anti-inflammatory and anti-fibrosis, and to delay organ fibrosis. This review may function as a potential orientation for the treatment of organ fibrosis with MSCs.

Key words: mesenchymal stem cells(MSCs), therapy, pulmonary fibrosis(PF), Wnt signaling pathway, hepatocyte growth factor(HGF)

中图分类号:

陈民佳, 汪晓月, 陈客宏, 陆红祥. 间充质干细胞治疗肺纤维化的研究进展[J]. 基础医学与临床, 2021, 41(7): 1056-1059.

CHEN Min-jia, WANG Xiao-yue, CHEN Ke-hong, LU Hong-xiang. Research progress of mesenchymal stem cells in the treatment of pulmonary fibrosis[J]. Basic & Clinical Medicine, 2021, 41(7): 1056-1059.

参考文献

[1]Harrell CR, Jankovic MG, Fellabaum C, et al. Molecular mechanisms responsible for anti-inflammatory and immunosuppressive effects of mesenchymal stem cell-derived factors[J]. Adv Exp Med Biol, 2019, 1084:187-206.
[2]Nagubothu SR, Sugars RV, Tudzarovski N, et al. Mesenchymal stromal cells modulate tissue repair responses within the injured vocal fold[J]. Laryngoscope, 2020, 130:E21-E29.
[3]Cahill EF, Kennelly H, Carty F, et al. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-induced pulmonary fibrosis[J]. Stem Cells Transl Med, 2016, 5:1307-1318.
[4]Sherman LS, Shaker M, Mariotti V, et al. Mesenchymal stromal/stem cells in drug therapy: new perspective[J]. Cytotherapy, 2017, 19:19-27.
[5]Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues[J]. Transplantation, 1968, 6:230-247.
[6]Cheng SL, Lin CH, Yao CL. Mesenchymal stem cell Administration in patients with chronic obstructive pulmonary disease: state of the science[J]. Stem Cells Int, 2017, 2017:8916570.doi: 10.1155/2017/8916570.
[7]Luna GLF, Russo TL, Sabadine MA, et al. Effects of mesenchymal stromal cells on motor function and collagen in the skeletal muscles of rats with type I diabetes[J]. Int J Exp Pathol, 2019, 100:359-368.
[8]Weiss ARR, Lee O, Eggenhofer E, et al. Differential effects of heat-inactivated, secretome-deficient MSC and metabolically active MSC in sepsis and allogenic heart transplantation[J]. Stem Cells, 2020, 38:797-807.
[9]Reddy M, Fonseca L, Gowda S, et al. Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin induced pulmonary fibrosis: comparison with pirfenidone[J]. Int J Stem Cells, 2016, 9:192-206.
[10]Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial[J]. Chest, 2017, 151:971-981.
[11]Felix RG, Bovolato ALC, Cotrim OS, et al. Adipose-derived stem cells and adipose-derived stem cell-conditioned medium modulate in situ imbalance between collagen I- and collagen V-mediated IL-17 immune response recovering bleomycin pulmonary fibrosis[J]. Histol Histopathol, 2020, 35:289-301.
[12]Zhao MM, Cui JZ, Cui Y, et al. Therapeutic effect of exogenous bone marrowderived mesenchymal stem cell transplantation on silicosis via paracrine mechanisms in rats[J]. Mol Med Rep, 2013, 8:741-746.
[13]Chen W, Wang S, Xiang H, et al. Microvesicles derived from human Wharton's Jelly mesenchymal stem cells ameliorate acute lung injury partly mediated by hepatocyte growth factor[J]. Int J Biochem Cell Biol, 2019, 112:114-122.
[14]Chen Z, Wu Z, Ning W. Advances in molecular mechanisms and treatment of radiation-induced pulmonary fibrosis[J]. Transl Oncol, 2019, 12:162-169.
[15]Klein D, Steens J, Wiesemann A, et al. Mesenchymal stem cell therapy protects lungs from radiation-induced endothelial cell loss by restoring superoxide dismutase 1 expression[J]. Antioxid Redox Signal, 2017, 26:563-582.
[16]Chen HX, Xiang H, Xu WH, et al. Manganese superoxide dismutase gene-modified mesenchymal stem cells attenuate acute radiation-induced lung injury[J]. Hum Gene Ther, 2017, 28:523-532.
[17]Kursova LV, Konoplyannikov AG, Pasov VV, et al. Possibilities for the use of autologous mesenchymal stem cells in the therapy of radiation-induced lung injuries[J]. Bull Exp Biol Med, 2009, 147:542-546.
[18]谯智慧, 张丹, 熊玮. 8例临床级脐带间充质干细胞治疗放射性肺纤维化的观察[J]. 第三军医大学学报, 2017, 39:1017-1018.
[19]Xu S, Liu C, Ji HL. Concise Review: Therapeutic potential of the mesenchymal stem cell derived secretome and extracellular vesicles for radiation-induced lung injury: progress and hypotheses[J]. Stem Cells Transl Med, 2019, 8:344-354.
[20]Mizuno S, Matsumoto K, Li MY, et al. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis[J]. FASEB J, 2005, 19:580-582.
[21]Wang H, Yang YF, Zhao L, et al. Hepatocyte growth factor gene-modified mesenchymal stem cells reduce radiation-induced lung injury[J]. Hum Gene Ther, 2013, 24:343-353.
[22]Li X, An G, Wang Y, et al. Targeted migration of bone marrow mesenchymal stem cells inhibits silica-induced pulmonary fibrosis in rats[J]. Stem Cell Res Ther, 2018, 9:335.doi: 10.1186/s13287-018-1083-y.
[23]Li X, Wang Y, An G, et al. Bone marrow mesenchymal stem cells attenuate silica-induced pulmonary fibrosis via paracrine mechanisms[J]. Toxicol Lett, 2017, 270:96-107.
[24]Jiang R, Liao Y, Yang F, et al. SPIO nanoparticle-labeled bone marrow mesenchymal stem cells inhibit pulmonary endoMT induced by SiO₂[J]. Exp Cell Res, 2019, 383:111492.doi: 10.1016/j.yexcr.2019.07.005.
[25]赵娜, 吴洁, 宋向荣, 等.骨髓间充质干细胞治疗矽肺小鼠肺纤维化效果[J]. 中国职业医学, 2017, 044:657-663.
[26]Zhang E, Yang Y, Chen S, et al. Bone marrow mesenchymal stromal cells attenuate silica-induced pulmonary fibrosis potentially by attenuating Wnt/beta-catenin signaling in rats[J]. Stem Cell Res Ther,2018,9:311.doi: 10.1186/s13287-018-1045-4.